{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:23:14Z","timestamp":1774578194190,"version":"3.50.1"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple myeloma (MM) is a complex hematological malignancy with heterogeneous clinical and pathophysiological backgrounds that influence treatment responses and outcomes. Identifying biomarkers to predict drug response and guide treatment decisions, particularly regarding drug combinations, is essential to improve therapeutic efficacy and patient outcomes. This study explores the role of microRNAs (miRNAs\/miRs) derived from bone marrow (BM) and peripheral blood (PB) in responses to treatment and survival outcomes in newly diagnosed MM (ndMM) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included twenty patients with ndMM undergoing first-line treatment with bortezomib, thalidomide, and dexamethasone. The miRNAs were isolated from BM and PB, and their profiles were analyzed using Next-Generation Sequencing (NGS), followed by validation of differentially expressed miRNAs by quantitative real-time PCR (qPCR). Clinical and response data were collected to assess correlations between miRNA levels, clinical characteristics, and patient outcomes. <jats:italic>In silico<\/jats:italic> analysis for target-prediction and gene ontology (GO) enrichment was performed to explore the potential biological and functional role of the identified miRNAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NGS profiling revealed several miRNAs differently expressed between treatment-refractory and sensitive patients, as well as between PB and BM. Among these, miR-665, miR-483-5p, miR-143-3p and miR-145-5p were selected for further validation by qPCR. It was observed that miR-665 was significantly elevated in treatment-refractory patients compared to treatment-sensitive patients. Additionally, miR-665 levels were higher in PB than in BM. Elevated miR-665 levels were associated with more aggressive disease characteristics and poorer clinical outcomes, including reduced overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our preliminary findings suggest that miR-665 could potentially serve as a non-invasive tool for predicting drug resistance and guiding treatment decisions in MM. These findings also highlight the potential utility of miRNAs in liquid biopsies as a predictive tool of drug response in MM and could pave the way for personalized treatment strategies, improving patient outcomes. Future research is needed to validate these results in larger cohorts and explore the underlying mechanisms of miR-665 in MM pathogenesis and drug resistance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1465814","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:54:07Z","timestamp":1746521647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study"],"prefix":"10.3389","volume":"16","author":[{"given":"Rui","family":"Bergantim","sequence":"first","affiliation":[]},{"given":"Sara","family":"Peixoto da Silva","sequence":"additional","affiliation":[]},{"given":"Vanessa","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joana M.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[]},{"given":"Rune","family":"Matthiesen","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 E.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"M. Helena","family":"Vasconcelos","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1302811","DOI":"10.1155\/2021\/1302811","article-title":"Methods to analyze time-to-event data: the Cox regression analysis","volume":"2021","author":"Abd ElHafeez","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"60723","DOI":"10.18632\/oncotarget.11032","article-title":"Role of micro-RNAs in drug resistance of multiple myeloma","volume":"7","author":"Abdi","year":"2016","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/leu.2013.262","article-title":"MicroRNA theragnostics for the clinical management of multiple myeloma","volume":"28","author":"Ahmad","year":"2014","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/cells10020448","article-title":"Potential role of microRNAs in inducing drug resistance in patients with multiple myeloma","volume":"10","author":"Allegra","year":"","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/cells10020448","article-title":"Potential role of microRNAs in inducing drug resistance in patients with multiple myeloma","volume":"10","author":"Allegra","year":"","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymeth.2018.09.002","article-title":"miARma-Seq, a comprehensive pipeline for the simultaneous study and integration of miRNA and mRNA expression data","volume":"152","author":"Andr\u00e9s-Le\u00f3n","year":"2019","journal-title":"Methods."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood-2023-185134","article-title":"Extracellular vesicles secreted from daratumumab resistant cells promote resistance and proliferation of daratumumab sensitive cells, possibly through the transfer of miRNA cargo","volume":"142","author":"Azaman","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41417-019-0154-2","article-title":"BAG3 regulates multiple myeloma cell proliferation through FOXM1\/Rb\/E2F axis","volume":"27","author":"Bai","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"B9","article-title":"The role of MicroRNAs in mature B-cell neoplasias drug resistance","volume-title":"Reference module in biomedical Sciences","author":"Bergantim","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13686","DOI":"10.3390\/ijms232213686","article-title":"Detection of measurable residual disease biomarkers in extracellular vesicles from liquid biopsies of multiple myeloma patients-A proof of concept","volume":"23","author":"Bergantim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0137294","DOI":"10.1371\/journal.pone.0137294","article-title":"Circulating serum MicroRNA-130a as a novel putative marker of extramedullary myeloma","volume":"10","author":"Besse","year":"2015","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"830922","DOI":"10.3389\/fonc.2022.830922","article-title":"Risk stratification before and during treatment in newly diagnosed multiple myeloma: from clinical trials to the real-world setting","volume":"12","author":"Bonello","year":"2022","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/bjh.12828","article-title":"MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma","volume":"165","author":"Campo","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/cancers13174365","article-title":"miR-22 modulates lenalidomide activity by counteracting MYC addiction in multiple myeloma","volume":"13","author":"Caracciolo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1182\/blood-2004-08-2985","article-title":"Multifunctional role of Erk5 in multiple myeloma","volume":"105","author":"Carvajal-Vergara","year":"2005","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"D127-D131","DOI":"10.1093\/nar\/gkz757","article-title":"miRDB: an online database for prediction of functional microRNA targets","volume":"48","author":"Chen","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4939-6728-5_6","article-title":"Small RNA library construction for exosomal RNA from biological samples for the Ion torrent PGM\u2122 and Ion S5\u2122 System","volume":"1545","author":"Cheng","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B19","volume-title":"IBM SPSS Statistics for windows, version 29.0.2.0","author":"Corp","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/cells10010101","article-title":"MiR-26a-5p as a reference to normalize MicroRNA qRT-PCR levels in plasma exosomes of pediatric hematological malignancies","volume":"10","author":"Damanti","year":"2021","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.trecan.2020.07.001","article-title":"BAG3 in tumor resistance to therapy","volume":"6","author":"De Marco","year":"2020","journal-title":"Trends Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100732","DOI":"10.1016\/j.blre.2020.100732","article-title":"Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity","volume":"46","author":"Diamond","year":"2021","journal-title":"Blood Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","article-title":"Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt","volume":"4","author":"Durinck","year":"2009","journal-title":"Nat. Protoc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/BS9.0000000000000160","article-title":"Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma","volume":"5","author":"Fang","year":"2023","journal-title":"Blood Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-disease- and treatment-related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2011.03.010","article-title":"Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice","volume":"81","author":"Giovannetti","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clml.2019.09.103","article-title":"MicroRNA analysis in multiple myeloma and extramedullary disease","volume":"19","author":"Gregorova","year":"2019","journal-title":"Clin. Lymphoma, Myeloma Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"862524","DOI":"10.3389\/fcell.2022.862524","article-title":"Exosomal miR-483-5p in bone marrow mesenchymal stem cells promotes malignant progression of multiple myeloma by targeting TIMP2","volume":"10","author":"Gu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.3390\/cancers15204915","article-title":"Hsa-miR-665 is a promising biomarker in cancer prognosis","volume":"15","author":"Guan","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/leu.2009.274","article-title":"Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling","volume":"24","author":"Guti\u00e9rrez","year":"2010","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers11111738","article-title":"The role and function of microRNA in the pathogenesis of multiple myeloma","volume":"11","author":"Handa","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1101\/gr.268490.120","article-title":"A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes","volume":"31","author":"Harman","year":"2021","journal-title":"Genome Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","author":"Hern\u00e1ndez-Rivas","year":"2022","journal-title":"Biomark. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/cancers13020306","article-title":"WWC proteins: important regulators of hippo signaling in cancer","volume":"13","author":"H\u00f6ffken","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3892\/ijmm.2016.2480","article-title":"Effect of silencing HOXA5 gene expression using RNA interference on cell cycle and apoptosis in Jurkat cells","volume":"37","author":"Huang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1007\/s12032-012-0210-3","article-title":"Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma","volume":"29","author":"Huang","year":"2012","journal-title":"Med. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ncrna9060068","article-title":"Dysregulation of non-coding RNAs: roles of miRNAs and lncRNAs in the pathogenesis of multiple myeloma","volume":"9","author":"Ismail","year":"2023","journal-title":"Noncoding RNA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1080\/10428194.2020.1788014","article-title":"Primary refractory multiple myeloma: a real-world experience with 85 cases","volume":"61","author":"Jurczyszyn","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01683-w","article-title":"Circulating biosignatures in multiple myeloma and their role in multidrug resistance","volume":"22","author":"Krishnan","year":"2023","journal-title":"Mol. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.2013.093500","article-title":"Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Kubiczkova","year":"2014","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/bloodadvances.2020003996","article-title":"Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches","volume":"5","author":"Lahuerta","year":"2021","journal-title":"Blood Adv."},{"key":"B49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ijlh.13367","article-title":"MicroRNAs in urine as diagnostic biomarkers for multiple myeloma","volume":"43","author":"Li","year":"2021","journal-title":"Int. J. Laboratory Hematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.12659\/MSM.918295","article-title":"EXT1, regulated by MiR-665, promotes cell apoptosis via ERK1\/2 signaling pathway in acute lymphoblastic leukemia","volume":"25","author":"Liu","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2021-146619","article-title":"Outcomes among primary refractory multiple myeloma patients in the era of monoclonal antibodies: the yale experience","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1080\/21655979.2021.2024389","article-title":"Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia","volume":"13","author":"Liu","year":"2022","journal-title":"Bioengineered"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","article-title":"A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance","volume":"124","author":"Liu","year":"2014","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.24131","article-title":"Outcomes of primary refractory multiple myeloma and the impact of novel therapies","volume":"90","author":"Majithia","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaav1741","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science."},{"key":"B59","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"B62","doi-asserted-by":"publisher","first-page":"979569","DOI":"10.3389\/fonc.2022.979569","article-title":"Aberrant DNA methylation in multiple myeloma: a major obstacle or an opportunity?","volume":"12","author":"Muylaert","year":"2022","journal-title":"Front. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cancers15061715","article-title":"MicroRNA-483-5p inhibits hepatocellular carcinoma cell proliferation, cell steatosis, and fibrosis by targeting PPAR\u03b1 and TIMP2","volume":"15","author":"Niture","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1182\/blood.v128.22.4421.4421","article-title":"Myeloma cells induce high level of TAF12 expression in bone marrow stromal cells, resulting in increased osteoclastogenesis and myeloma cell growth in response to 1,25(OH)2D3","volume":"128","author":"Ohata","year":"2016","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"W169","DOI":"10.1093\/nar\/gkt393","article-title":"DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows","volume":"41","author":"Paraskevopoulou","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3389\/fonc.2019.01137","article-title":"KRAS\/NRAS\/BRAF mutations as potential targets in multiple myeloma","volume":"9","author":"Pasca","year":"2019","journal-title":"Front. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3389\/fonc.2019.01404","article-title":"MicroRNAs in tumor cell metabolism: roles and therapeutic opportunities","volume":"9","author":"Pedroza-Torres","year":"2019","journal-title":"Front. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semcancer.2021.03.014","article-title":"miRNAs mediated drug resistance in hematological malignancies","volume":"83","author":"Peixoto da Silva","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hon.3208","article-title":"Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma","volume":"41","author":"Perroud","year":"2023","journal-title":"Hematol. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/b:bile.0000019559.84305.47","article-title":"Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations","volume":"26","author":"Pfaffl","year":"2004","journal-title":"Biotechnol. Lett."},{"key":"B71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12859-018-2533-3","article-title":"GOnet: a tool for interactive Gene Ontology analysis","volume":"19","author":"Pomaznoy","year":"2018","journal-title":"BMC Bioinforma."},{"key":"B73","volume-title":"GraphPad prism, version 10.0.0 for mac","author":"Prism","year":"2024"},{"key":"B74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12032-014-0219-x","article-title":"Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma","volume":"31","author":"Qu","year":"2014","journal-title":"Med. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/2211536610666210412155206","article-title":"High expression of miR-483-5p predicts chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Rattanapan","year":"2021","journal-title":"Microrna"},{"key":"B78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2014.155","article-title":"Circulating miRNA markers show promise as new prognosticators for multiple myeloma","volume":"28","author":"Rocci","year":"","journal-title":"Leukemia"},{"key":"B80","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1586\/14737159.2014.946906","article-title":"The potential of miRNAs as biomarkers for multiple myeloma","volume":"14","author":"Rocci","year":"","journal-title":"Expert Rev. Mol. Diagn"},{"key":"B81","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","article-title":"Quality control and preprocessing of metagenomic datasets","volume":"27","author":"Schmieder","year":"2011","journal-title":"Bioinformatics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1083\/jcb.201708168","article-title":"Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation","volume":"217","author":"Sha","year":"2018","journal-title":"J. Cell Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/cancers12010200","article-title":"Deep sequencing analysis reveals distinctive non-coding RNAs when comparing tumor multidrug-resistant cells and extracellular vesicles with drug-sensitive counterparts","volume":"12","author":"Sousa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1038\/onc.2014.254","article-title":"MicroRNA regulons in tumor microenvironment","volume":"34","author":"Suzuki","year":"2015","journal-title":"Oncogene"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41374-018-0169-6","article-title":"miR-483-5p decreases the radiosensitivity of nasopharyngeal carcinoma cells by targeting DAPK1","volume":"99","author":"Tian","year":"2019","journal-title":"Lab. Invest"},{"key":"B88","first-page":"3147","article-title":"Effect of miR-483-5p on apoptosis of lung cancer cells through targeting of RBM5","volume":"11","author":"Wang","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"106769","DOI":"10.1016\/j.leukres.2021.106769","article-title":"MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)","volume":"112","author":"Wang","year":"2022","journal-title":"Leuk. Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.2147\/CMAR.S241795","article-title":"miR-665 suppresses the epithelial-mesenchymal transition and progression of gastric cancer by targeting CRIM1","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698197","article-title":"Circulating miRNAs as auxiliary diagnostic biomarkers for multiple myeloma: a systematic review, meta-analysis, and recommendations","volume":"11","author":"Xiang","year":"2021","journal-title":"Front. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10142-023-01055-7","article-title":"RefFinder: a web-based tool for comprehensively analyzing and identifying reference genes","volume":"23","author":"Xie","year":"2023","journal-title":"Funct. Integr. Genomics"},{"key":"B93","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1080\/03610918.2020.1837165","article-title":"Robust RNA-seq data analysis using an integrated method of ROC curve and Kolmogorov-Smirnov test","volume":"51","author":"Yang","year":"2022","journal-title":"Commun. Stat. Simul. Comput."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1590\/S1677-5538.IBJU.2016.0595","article-title":"miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5","volume":"43","author":"Yang","year":"2017","journal-title":"Int. Braz J. Urol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3390\/biom12081150","article-title":"The proteasome activator pa200\/PSME4: an emerging new player in Health and disease","volume":"12","author":"Yazgili","year":"2022","journal-title":"Biomolecules"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","article-title":"microRNAs as oncogenes and tumor suppressors","volume":"302","author":"Zhang","year":"2007","journal-title":"Dev. Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1007\/s11427-015-4969-2","article-title":"The role of circulating miRNAs in multiple myeloma","volume":"58","author":"Zhang","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"30876","DOI":"10.18632\/oncotarget.9021","article-title":"Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B99","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10495-023-01909-2","article-title":"Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis","volume":"29","author":"Zhang","year":"2023","journal-title":"Apoptosis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.3892\/ol.2018.8157","article-title":"The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma","volume":"15","author":"Zhu","year":"2018","journal-title":"Oncol. Lett."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0119857","DOI":"10.1371\/journal.pone.0119857","article-title":"Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells","volume":"10","author":"Zub","year":"2015","journal-title":"PLoS One"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/16078454.2022.2124694","article-title":"Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma","volume":"27","author":"Zuo","year":"2022","journal-title":"Hematology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1465814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:54:10Z","timestamp":1746521650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1465814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":102,"alternative-id":["10.3389\/fphar.2025.1465814"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1465814","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1465814"}}